Androst-4-ene-3,17-diones and process for their preparation
AssigneeFarmitalia Carlo Ebra S.r.l.
InventorsFranco Buzzetti, Enrico di Salle, Paolo Lombardi
Life of this patent
Estimating the term…
Abstract
The present invention relates to new 6-substituted 1.2.beta.methylenandrost-4-ene-3,17-diones of the following general formula: ##STR1## wherein one of R.sub.1 and R.sub.2 is hydrogen and the other is halogen, amino or azido, or R.sub.1 and R.sub.2, taken together, form a .dbd.CH.sub.2 or .dbd.O group, and, when one of R.sub.1 and R.sub.2 is amino, the pharmaceutically acceptable salts thereof. The compounds of the invention are useful in therapy, in particular as anti-cancer agents.
Claims5
A compound having the formula (I) ##STR4## wherein one of R.sub.1 and R.sub.2 is hydrogen and the other is amino or azido, or R.sub.1 and R.sub.2, taken together, form a .dbd.CH.sub.2 or .dbd.O group, and, when one of R.sub.1 and R.sub.2 is amino, the pharmaceutically acceptable salts thereof.
6-methylene-1,2.beta.-Methyleneandrost-4-ene-3,17-dione.
A compound selected from the group consisting of:
- 6.beta.-amino-1,2.beta.-methyleneandrost-4-ene-3,17-dione
- 6.alpha.-amino-1,2.beta.-methyleneandrost-4-ene-3,17-dione
- 6.beta.-azido-1,2.beta.-methyleneandrost-4-ene-3,17-dione
- 6.alpha.-azido-1,2.beta.-methyleneandrost-4-ene-3,17-dione;
- and
- 1,2.beta.-methyleneandrost-4-ene-3,6,17-trione;
- and the pharmaceutically acceptable salts of the 6-amino derivatives hereabove mentioned.
Dependencies are inferred from the claim text.